**Novartis Launches Tender Offer to Acquire Tourmaline Bio for $48 Per Share**
**BASEL, Switzerland** – Global healthcare company Novartis announced Monday it has commenced a cash tender offer to acquire all outstanding shares of Tourmaline Bio, Inc.
The offer, made through a Novartis subsidiary, is for $48 per share. It follows a merger agreement between the two companies dated September 8, 2025. Novartis, a Swiss firm, is seeking to purchase the Delaware-incorporated biopharmaceutical company Tourmaline to expand its portfolio.
The tender offer was initiated on September 29, 2025, and is scheduled to expire at 11:59 p.m. ET on October 27, 2025, unless extended. Tourmaline’s board of directors has recommended that its stockholders accept the offer.
The acquisition is contingent on customary closing conditions, including the tender of a majority of Tourmaline’s outstanding shares and the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The deal is not subject to a financing condition.
Related Articles:
- https://nobot.news/trump-u-s-establishes-strategic-bitcoin-reserve-in-landmark-executive-order/
- https://nobot.news/bekaert-partners-with-edison-next-for-a-6-1-mw-solar-installation-on-sardinia-italy/
- https://nobot.news/german-exports-fell-by-1-4-in-may-2025